不同序贯的C225与化疗药物对人胃腺癌细胞株SGC-7901的抗瘤作用影响  

Anti -Proliferative effects of monoclonal antibody C225 and cytotoxic drugs with different sequence to SGC - 7901 cell lines

作　　者：刘芳[1] 刘杰 张华[1] 于雁[1] 钱路静[3] 尚丽华[1] 胡静[1] 车德海[1] 

机构地区：[1]哈尔滨医科大学附属第三医院肿瘤内六科,哈尔滨150081 [2]鹤岗矿务局有限责任公司总医院消化内科 [3]厦门市第三医院

出　　处：《实用肿瘤学杂志》2013年第1期42-45,共4页Practical Oncology Journal

基　　金：黑龙江省教育厅科学技术研究资助项目（11541248）

摘　　要：目的探讨不同序贯的阿妥昔单抗（Cetuximab，C225）与化疗药物联合对人胃腺癌细胞株SGC-7901的增殖抑制作用，寻找治疗胃癌的新方法、新配方。方法选用浓度递增的Cetuximab和化疗药物奥沙利铂、氟尿嘧啶、卡培他滨，分别按照不同给药方式单药、序贯作用于SGC-790l细胞，采用细胞计数试剂盒检测不同给药方式对SGC-7901细胞的增殖抑制作用，计算不同序贯给药时Cetuximab和化疗药物的半数抑制浓度（1C50）的变化，及其l卡}I瓦作川的协同系数（CI）。结果Cetuximab和化疗药物联用对SGC-7901细胞的增殖抑制作用受给药序贯影响：Cetuximab先于化疗药物给药，两者的IC50较单用时降低，但cI值均大于l，两者之间为拈抗效应；Cetuximab后于化疗药物给药，两者的IC50较单川时降低更为明显，且cI值均小于1，两者之间具有较明品的协同效应。结论Cetuximab联合化疔药物对胃癌细胞SGC-7901的增殖具有协同抑制作用，化疗药物先于Cetuximab的序贯给药方式能获得明显的协同效应。Objective To evaluate inhibition effecton proliferation of SCG -7901 cell in different se- quences comlfination of Cetuximab with either oxaliplafin, funaioniding or Capeeitabine. To explore the optimal treatmenl schedule of combination of Cetuximab and eytotoxic drngs. Methods Increasing concentration of Celuximab（5 -500 rag/L）eombined with increasing concentration cytotoxic drugs was administrated to human gaslrie cancer cell lines SCG- 7901 with different sequences. The prolilbration inhihition eftet on SCG -7901 cell was detected with CCK -8 assay. The IC50 and CIef Cetuximab and either eytotoxie drugs were eahulated. Results The eombinalion of a eytotoxie drug with Celuximab caused differeul antiproliferatiw effees on SCG - 7901 cells depending on diflerenl treatment sequenees. The respective 1C50 nf Cet/iximab and eytotoxie drugs decreased when （eluxima） followed by chemotherapy,while the CI values were all 〉 I , which indicated an antagonistic interaction. In eonlrasl, wh chemotherapy was tllowed by Cetuximab, the respective50 of drugs decreased more remarkably aud lhe （21 wl.lues were all 〈 I ,which indicated a signitieanl synergistic auliprolib,raliwlivily and conduce to less doses and mihler side effecls in cliuical application.

关 键 词：胃癌 西妥昔单抗 细胞株 联合化疗 

分 类 号：R735.2[医药卫生—肿瘤]